Susan Chang
This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.
PRIMARY OBJECTIVES: I. To assess the safety and feasibility of hyperpolarized 13C MR metabolic imaging as a new and unique tool for evaluating tumor burden and detecting early response to therapy in participants with glioma. II. To define the most appropriate imaging parameters for obtaining hyperpolarized 13C data from the brain, one hundred participants with evidence of residual disease from a prior MRI examination will have hyperpolarized metabolic imaging after receiving one or two injections of hyperpolarized 13 C pyruvate. For participants who are willing to receive two injections, the…
Inclusion Criteria: For Participants in Cohort 1: Suspected or histologically proven glioma who have evidence of evaluable disease based on a prior magnetic resonance (MR) scan. For Participants in Cohort 2: Histologically proven glioma who will be undergoing treatment. To be included in the study all subjects must also meet the following criteria: 1. Participants must be \> 18 years old and with a life expectancy \> 12 weeks. 2. Participants must have a Karnofsky performance status of ≥ 60. 3. Participants must have adequate renal function (creatinine \< 1.5 mg/dL) before starting therapy…
Given IV
Undergo MRI
Undergo radiation therapy for cancer outside of this study.
Undergo chemotherapy for cancer outside of this study.
Arctuva estimate
Verify or correct the compensation shown for this listing.